MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
Guardant Health Total Assets 2011-2026 | GH
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Guardant Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.49 B | 1.79 B | 1.61 B | 2.2 B | 2.27 B | 963 M | 587 M | 343 M | 117 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.27 B | 117 M | 1.26 B |
Quarterly Total Assets Guardant Health
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.33 B | 1.34 B | 1.49 B | 1.54 B | 1.61 B | 1.7 B | 1.79 B | 1.8 B | 1.84 B | 1.51 B | 1.61 B | 1.7 B | - | 2.13 B | 2.2 B | 2.23 B | 2.29 B | 2.35 B | 2.27 B | 2.27 B | 2.27 B | 2.27 B | 963 M | 963 M | 963 M | 963 M | 587 M | 587 M | 587 M | 587 M | 343 M | 343 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.35 B | 343 M | 1.5 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 23.11 | 4.52 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 23.0 | 2.86 % | $ 248 M |  China |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.6 | -0.22 % | $ 2.03 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 6.1 | 1.16 % | $ 179 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 39.93 | -1.67 % | $ 1.11 B | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 234.99 | -0.25 % | $ 172 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.98 | 6.97 % | $ 368 M | Israel |
 |
DexCom
DXCM
|
6.26 B | $ 68.47 | -2.33 % | $ 26.4 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 17.5 | -7.41 % | $ 941 M | USA |
 |
Celcuity
CELC
|
245 M | $ 105.54 | -3.33 % | $ 4.16 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.4 | 3.66 % | $ 108 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.77 | 0.14 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 27.9 | -0.39 % | $ 844 M | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | $ 48.19 | 1.71 % | $ 10.7 B |  Niderland |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 146.41 | -2.48 % | $ 23.3 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 214.0 | -1.51 % | $ 11 B | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 243.4 | -0.36 % | $ 44.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 177.06 | -0.64 % | $ 19.7 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 5.77 | -3.27 % | $ 748 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 254.76 | 0.43 % | $ 21.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 189.39 | -6.67 % | $ 15.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 708.9 | -0.79 % | $ 58.5 B | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 68.27 | -1.59 % | $ 4.72 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 145.56 | -1.51 % | $ 44.3 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.83 | 1.8 % | $ 6.5 M | USA |
 |
Bioventus
BVS
|
811 M | $ 8.0 | 5.12 % | $ 501 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 29.47 | 1.25 % | $ 20 B | Niderland |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
18.1 M | $ 23.85 | 2.49 % | $ 31 M | USA |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 461.94 | -0.56 % | $ 31 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 6.63 | -0.08 % | $ 601 M | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 4.64 | 1.75 % | $ 2.49 M | USA |